Zoetis (ZTS) Competitors $142.43 -2.22 (-1.53%) Closing price 03:59 PM EasternExtended Trading$142.30 -0.13 (-0.09%) As of 05:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ZTS vs. IDXX, MRK, PFE, BMY, RPRX, JAZZ, CORT, PRGO, SUPN, and PCRXShould you be buying Zoetis stock or one of its competitors? The main competitors of Zoetis include IDEXX Laboratories (IDXX), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol Myers Squibb (BMY), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Corcept Therapeutics (CORT), Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), and Pacira BioSciences (PCRX). These companies are all part of the "medical" sector. Zoetis vs. Its Competitors IDEXX Laboratories Merck & Co., Inc. Pfizer Bristol Myers Squibb Royalty Pharma Jazz Pharmaceuticals Corcept Therapeutics Perrigo Supernus Pharmaceuticals Pacira BioSciences IDEXX Laboratories (NASDAQ:IDXX) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations. Do analysts prefer IDXX or ZTS? IDEXX Laboratories presently has a consensus target price of $649.44, indicating a potential upside of 0.16%. Zoetis has a consensus target price of $200.88, indicating a potential upside of 41.03%. Given Zoetis' higher possible upside, analysts plainly believe Zoetis is more favorable than IDEXX Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IDEXX Laboratories 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.80Zoetis 0 Sell rating(s) 4 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.56 Which has preferable valuation and earnings, IDXX or ZTS? Zoetis has higher revenue and earnings than IDEXX Laboratories. Zoetis is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIDEXX Laboratories$3.90B13.31$887.87M$12.0153.99Zoetis$9.26B6.82$2.49B$5.8124.52 Does the media prefer IDXX or ZTS? In the previous week, Zoetis had 9 more articles in the media than IDEXX Laboratories. MarketBeat recorded 36 mentions for Zoetis and 27 mentions for IDEXX Laboratories. IDEXX Laboratories' average media sentiment score of 1.68 beat Zoetis' score of 1.60 indicating that IDEXX Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEXX Laboratories 25 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Zoetis 34 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do institutionals & insiders believe in IDXX or ZTS? 87.8% of IDEXX Laboratories shares are owned by institutional investors. Comparatively, 92.8% of Zoetis shares are owned by institutional investors. 1.0% of IDEXX Laboratories shares are owned by insiders. Comparatively, 0.2% of Zoetis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more volatility and risk, IDXX or ZTS? IDEXX Laboratories has a beta of 1.56, meaning that its stock price is 56% more volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. Is IDXX or ZTS more profitable? Zoetis has a net margin of 27.83% compared to IDEXX Laboratories' net margin of 24.41%. IDEXX Laboratories' return on equity of 64.42% beat Zoetis' return on equity.Company Net Margins Return on Equity Return on Assets IDEXX Laboratories24.41% 64.42% 29.89% Zoetis 27.83%56.90%19.54% SummaryIDEXX Laboratories beats Zoetis on 11 of the 17 factors compared between the two stocks. Get Zoetis News Delivered to You Automatically Sign up to receive the latest news and ratings for ZTS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZTS vs. The Competition Export to ExcelMetricZoetisMED IndustryMedical SectorNYSE ExchangeMarket Cap$63.12B$2.60B$5.74B$21.66BDividend Yield1.37%55.05%5.61%3.51%P/E Ratio24.5223.2176.4930.08Price / Sales6.82704.75551.4461.19Price / Cash20.6327.8325.8118.30Price / Book13.485.3213.624.64Net Income$2.49B$32.95M$3.29B$1.00B7 Day Performance-3.40%3.71%1.68%0.98%1 Month Performance-8.88%4.94%4.05%2.77%1 Year Performance-26.43%1.28%80.63%15.20% Zoetis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZTSZoetis4.8302 of 5 stars$142.43-1.5%$200.88+41.0%-24.9%$63.12B$9.26B24.5213,800Positive NewsIDXXIDEXX Laboratories4.1566 of 5 stars$643.99+0.4%$649.44+0.8%+27.1%$51.52B$4.04B53.6211,000Positive NewsAnalyst UpgradeMRKMerck & Co., Inc.4.9993 of 5 stars$81.07-1.1%$107.44+32.5%-31.3%$202.50B$64.17B12.4975,000Positive NewsPFEPfizer4.986 of 5 stars$23.98+0.5%$28.12+17.3%-18.3%$136.34B$63.63B12.7681,000Trending NewsAnalyst UpgradeOptions VolumeBMYBristol Myers Squibb4.9283 of 5 stars$46.34+0.3%$56.38+21.7%-9.0%$94.32B$47.70B18.6934,100Positive NewsDividend AnnouncementRPRXRoyalty Pharma4.8686 of 5 stars$35.15-3.3%$48.00+36.6%+30.2%$20.50B$2.26B20.3280Positive NewsJAZZJazz Pharmaceuticals4.4444 of 5 stars$125.22-0.7%$178.67+42.7%+17.5%$7.60B$4.09B-18.612,800Positive NewsCORTCorcept Therapeutics4.7732 of 5 stars$69.53-4.6%$135.25+94.5%+89.3%$7.33B$716.08M61.53300Positive NewsPRGOPerrigo4.7909 of 5 stars$21.76-2.3%$33.00+51.7%-23.1%$2.99B$4.37B-37.518,379Analyst DowngradeSUPNSupernus Pharmaceuticals3.0487 of 5 stars$43.99-3.2%$43.00-2.3%+47.6%$2.47B$665.13M38.25580PCRXPacira BioSciences3.431 of 5 stars$26.86-1.0%$30.83+14.8%+82.1%$1.21B$700.97M-9.66720Positive News Related Companies and Tools Related Companies IDEXX Laboratories Alternatives Merck & Co., Inc. Alternatives Pfizer Alternatives Bristol Myers Squibb Alternatives Royalty Pharma Alternatives Jazz Pharmaceuticals Alternatives Corcept Therapeutics Alternatives Perrigo Alternatives Supernus Pharmaceuticals Alternatives Pacira BioSciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ZTS) was last updated on 9/23/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zoetis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zoetis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZTS Stock Alerts